{"schema_version":"secwatch.filing_event.v1","accession":"0001773751-26-000019","form_type":"8-K","ticker":"HIMS","cik":"0001773751","company_name":"Hims & Hers Health, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.131906+00:00","generated_at":"2026-05-16T01:12:58.445660+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Hims & Hers FY2025 revenue up 59% to $2.35B, adj. EBITDA $318M; guides FY2026 rev $2.7-2.9B","bullets":["Revenue $2.35B (+59% YoY); net income $128M; adj. EBITDA $318M vs $177M prior year.","Q4 revenue $618M (+28% YoY); net income $20.6M; adj. EBITDA $66.3M.","Subscribers at 2.5M (+13% YoY); monthly revenue per avg subscriber $83 (+28% YoY).","FY2026 guidance: revenue $2.7-2.9B, adj. EBITDA $300-375M; excludes potential Eucalyptus acquisition.","Non-GLP-1 revenue majority; compounded semaglutide access assumed in guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001773751-26-000019","json":"https://secwatch.observer/filing/0001773751-26-000019.json","markdown":"https://secwatch.observer/filing/0001773751-26-000019.md","text":"https://secwatch.observer/filing/0001773751-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/0001773751-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:12:58.445660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}